Business
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is dev
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 ","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that it will present two posters on its VK2735 program at the 33rd European Congress on Obesity (ECO) taking place in Istanbul, Türkiye on May 12-15, 2026. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.","length":678,"tagName":"p"},{"type":"image","alt":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZacgsMHcTH4bVMkIFotjRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/273590/viking_9_15_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At ECO, Viking will present a poster highlighting data from its Phase 2 VENTURE-Oral Dosing trial, focusing on key efficacy and safety endpoints, including weight loss and tolerability during the 13-week study. The second poster will highlight the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or who are overweight and have at least one weight-related comorbidity.","length":440,"tagName":"p"},{"type":"text","content":"Details of the ECO poster presentations are as follows:","length":55,"tagName":"p"},{"type":"text","content":"Title: Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Co...